Selected publication milestones, not an exhaustive history or discovery priority claim.
1965 — chemical comparison documents nonidentical formulations and tests the proposed biological rationale. Original PMID14281087.
1975 — controlled tumour models test amygdalin with enzyme activation near tolerated doses and find no activity with increased toxicity. Original PMID1060511.
1978 — selected retrospective case submissions include judged responses but no definite attribution. Original PMID683212.
1981 — human pharmacology maps oral/IV and interacting-food differences. Original PMID7005480.
1982 — nonrandomized human metabolic-regimen trial finds no substantive benefit and toxicity hazards. Original PMID7033783.
2017 — prescribed oral tablets precede a clinically documented poisoning syndrome with antidote response. Original PMID28912981.
2020 — engineered magnetic-enzyme activation tests a different tumour-delivery platform in mice. Original PMID32636623.
2022 — niosomal-gel study measures restricted rat skin-tumour volume and local histology. Original PMID36355478.
2026 — nanocomposite cell assays explore uptake and delivery; human-regimen validation remains absent. Original PMID41882653.
Bridge cell concentrations to measured tumour and normal-organ exposure rather than equating plasma peak with sustained tumour concentration.
Separate free compound, historical products and new carrier/enzyme platforms.
Verify actual normal-tissue comparators and systemic cyanide margins for modern selectivity claims.
Resolve route, foods and microbial activation without assuming everyIVdose is safe or everyoral exposure is lethal.
Retain the difference between178 treated and175 evaluable, and label the temporary response detail as secondary-source verification until original body is obtained.
Do not use generic alternative-care mortality coding as a laetrile-specific causal estimate.
Audit current retractions before reusing older positive cell papers.
First characterize formulation identity, parent/metabolite kinetics and cyanide generation with clinically anchored exposure in matched malignant and normal systems. Establish selective functional activity, normal-organ margin and pharmacodynamic tumour exposure in controlled relevant models using carrier/enzyme-only and route-matched controls. A future new-platform add-on trial would require those preclinical criteria and independent review; it must preserve effective cancer care and is not a recommendation to revive the historical unbeneficial regimen.